The U.S. Food and Drug Administration (FDA) is changing the game on COVID-19 vaccines. Instead of approving yearly boosters ...

FDA changes COVID-19 vaccine approval policy, major trials now required for widespread use. Higher risk individuals still ...

The FDA has granted full approval for Novavax's COVID-19 vaccine, but with restrictions. Discover the details now.

BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The ...

According to Makary and Prasad, the US’s adoption of a “one-size-fits-all” guidance for COVID-19 vaccination departs from ...

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

WEDNESDAY May 21, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) has decided that only seniors and ...

Health experts say there are legitimate questions about how much everyone still benefits from yearly COVID vaccination or ...